Selective inhibition of the effects of phorbol ester on doxorubicin resistance and P-glycoprotein by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) in multidrug-resistant MCF-7/Dox human breast carcinoma cells

Biochemical Pharmacology

Volumn 52, Issue 3, 1996, Pages 393-399

  Ahn, Chang Ho ^a   Kong, Jae Yang ^a   Choi, Won Chul ^a   Hwang, Myung Sil ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

breast cancer; multidrug resistance; P glycoprotein; phorbol ester; protein kinase C

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 4ALPHA PHORBOL DIDECANOATE; DOXORUBICIN; GLYCOPROTEIN P; ISOENZYME; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RADIOISOTOPE;

ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 0030576654     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00240-7     Document Type: Article

References (45)

1. 1. Gottesman M and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
2. 2. Moscow JA and Cowan KH, Multidrug resistance. J Natl Cancer Institute 80: 14-20, 1988.
3. 3. Bradley G, Juranka PF and Ling V, Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
4. 4. Hayes JD and Wolf CR, Molecular mechanisms of drug resistance. Biochem J 272: 281-295, 1990.
5. 5. Beck WT, Drug accumulation and binding in P-glycoprotein-associated multidrug resistance. In: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (Ed. Roninson IB), pp. 215-227. Plenum Press, New York, 1991.
6. 6. Ford JM and Hait WN, Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
7. 7. Silbermann MH, Boersma AWM, Janssen ALW, Scheper RJ, Herweijer H and Nooter K, Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 44: 722-726, 1989.
8. 8. Coley HM, Twentyman PR and Workman P, Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 38: 4467-4475, 1989.
9. 9. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loo F, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233, 1991.
10. 10. Yang, C-P, DePinho SG, Greenberger LM, Arceci RJ and Horwitz SB, Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788, 1989.
11. 11. Ross DD, Wooten PJ, Tong Y, Cornblatt B, Levy C, Sridhara R, Lee EJ and Schiffer CA, Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. Blood 83: 1337-1347, 1994.
12. 12. Woodcock DM, Linsenmeye ME, Chojnowski G, Kriegle AB, Nink V, Webster LK and Sawyer WH, Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62-68, 1992.
13. 13. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S and Tritton TR, Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance. Cancer Commun 1: 285-292, 1989.
14. 14. Ford JM, Prozialeck WC and Hait WN, Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115, 1989.
15. 15. Ahn C-H and Kim JK, Characterization of protein kinase C in doxorubicin-sensitive and -resistant human breast MCF-7 cancer cell lines. J Biomed Res 1: 52-58, 1991.
16. 16. Lee SA, Karaszhiewicz JW and Anderson WB, Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52: 3750-3759, 1992.
17. 17. Fine RL, Patel J and Chabner BA, Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582-586, 1988.
18. γ 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine and phorbol esters. Cancer Res 47: 2860-2865, 1987.
19. 19. Fine RL, Ozol R, Patel J and Ahn C-H, Phosphoprotein, protein kinase C and second-messenger system changes in human multi-drug resistant cancer cells. In: Drug Resistance in Cancer Therapy (Ed. Ozol F), pp. 107-123. Kluwer Academic, New York, 1989.
20. 20. Chambers TC, McAvoy EM, Jacobs JW and Eilon G, Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679-7686, 1990.
21. 21. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepúlveda V and Higgins CF, Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14: 68-75, 1995.
22. 22. Lee YJ, Berns CM, Erdos G, Borrelli MJ, Ahn CH and Corry PM, Effect of 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) on HSP70 and HSP28 gene expression and thermotolerance development in human colon carcinoma cells. Biochem Pharmacol 48: 2057-2063, 1994.
23. 23. Bradford MM, A rapid and sensitive method tor the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
24. 24. Wiechelman K, Braun R and Fitzpatrick J, Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation. Anal Biochem 175: 231-237, 1988.
25. 25. Gates RE, Elimination of interfering substances in the presence of detergent in the bicinchoninic acid protein assay. Anal Biochem 196: 290-295, 1991.
26. 26. Fridman F, Lacal JC, Reich R, Bonfil DR and Ahn C-H, Differential effects of phorbol ester on the in vitro invasiveness of malignant and non-malignant human fibroblast cells. J Cell Physiol 142: 55-60, 1990.
27. 27. Chambers TC, Pohl J, Raynor RL and Kuo JF, Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268: 4592-4595, 1993.
28. 28. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA, Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC α. J Biol Chem 268: 658-664, 1993.
29. 29. Fan D, Fidler IJ, Ward NE, Seid C, Earnest LE, Housey GM and O'Brian CA, Stable expression of a cDNA encoding rat brain protein kinase C-βI confers a multidrug-resistant phenotype on rat fibroblasts. Anticancer Res 12: 661-667, 1992.
30. 30. Ahmad S, Trepel JB, Ohno S, Suzuki K, Tsuruo T and Glazer RI, Role of protein kinase C in the modulation of multidrug resistance: Expression of the atypical γ isoform of protein kinase C does not confer increased resistance to doxorubicin. Mol Pharmacol 42: 1004-1009, 1992.
31. 31. Mischak H, Pierce JH, Goodnight J, Kazanietz MG, Blumberg PM and Mushinski JF, Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-α and -δ and not by protein kinase C-βII, -ε, -ζ, and -η. J Biol Chem 268: 20110-20115, 1993.
32. 32. Murray, NR, Baumgardner GP, Burns DJ and Fields AP, Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that βII protein kinase C is required for proliferation. J Biol Chem 268: 15847-15853, 1993.
33. 33. Gupta S, Patel K, Singh H and Gollapudi S, Effect of calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: Reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76: 139-145, 1994.
34. 34. Miyamoti KI, Inoko K, Ikeda K, Wakusawa S, Kajita S, Hasegawa T, Takagi K and Koyama M, Effect of staurosporine derivatives on protein kinase activity and vinblastine accumulation in mouse leukemia P388/ADR cells. J Pharm Pharmacol 45: 43-47, 1993.
35. 35. Pereira E and Garnier-Suillerot A, Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem Pharmacol 47: 1851-1857, 1994.
36. 36. Laredo J, Huynh A, Muller C, Jaffrezou JP, Bailly JD, Cassar G, Laurent G and Demur C, Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood 84: 229-237, 1994.
37. 37. Yusa K and Tsuruo T, Reversal mechanism of multidrug-resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5002-5006, 1989.
38. 38. Foxwell BMJ, Mackie A, Ling V and Ryffel B, Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Mol Pharmacol 36: 543-546, 1989.
39. 39. Mimnaugh EG, Dusre L, Atwell J and Myers CE, Differential oxygen radical susceptibility of Adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. Cancer Res 49: 8-15, 1989.
40. 40. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan KH, Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
41. 41. Huet S, Schott B and Robert J, P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. Br J Cancer 65: 538-544, 1992.
42. 42. Efferth T and Volm M, Reversal of doxorubicin-resistance in Sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett 70: 197-202, 1993.
43. 43. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH and Law RE, Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994.
44. 2. FEBS Lett 348: 317-319, 1994.
45. 45. Wright SC, Zhong J and Larrick JW, Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 8: 654-660, 1994.